Validating Novel In Vitro Models & Building More Predictive Nonclinical Packages for Smarter ADC Preclinical Strategies

• Traditional nonclinical models often fail to predict clinical outcomes for complex ADCs, creating a need for more advanced and biologically relevant preclinical approaches.
• Novel in vitro systems can improve decision-making in drug discovery by providing better insights into key factors such as target uptake, payload characteristics, and tissue toxicity
• Integrating these systems into a broader translational strategy, along with improved species selection, biomarker use, and mechanistic data, can produce more predictive nonclinical packages and enable faster, more confident go/no-go decisions

Speakers:

Rakesh Dixit

President & Chief Executive Officer

Bionavigen